Nov 08,2022

Roche Diabetes Care showcases Integrated Diabetes Management Solution at CIIE

Roche featured two new glucose meter products, ACCU-CHEK® Instant Glucometer and ACCU-CHEK® Guide Me Glucometer, and a new digital diabetes management platform which aims to provide patients with professional and easier diabetes management solutions at the China International Import Expo (CIIE).

PRODUCT

#bgm

View Analyst & Ambassador Comments
Go to original news
Nov 08,2022

ASCENSIA DIABETES CARE ANNOUNCES GLOBAL INTEGRATION OF THE EVERSENSE CGM SYSTEM WITH APPLE HEALTH

Ascensia Diabetes Care announces that the Eversense® CGM app has been updated globally to seamlessly integrate with Apple Health. This means that people with diabetes using Eversense CGM Systems will now also have the option to view their glucose data within the Apple Health app, alongside other health metrics on the iPhone’s widely used health and wellbeing platform.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 08,2022

Senseonics Holdings, Inc. Reports Third Quarter 2022 Financial Results

Senseonics Holdings today reported financial results for the quarter ended September 30, 2022. Total revenue for the third quarter of 2022 was $4.6 million, compared to $3.5 million for the third quarter of 2021. U.S. revenue was $1.9 million in the third quarter of 2022, compared to $0.6 million in the prior year period, and revenue outside the U.S. was $2.7 million in the third quarter of 2022, compared to $2.9 million in the prior year period.

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 08,2022

Tandem Diabetes Care Announces Upcoming Conference Presentation

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022 at 9:00am Eastern Time (6:00am Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 09,2022

Global Smart Insulin Pens Market Report to 2030 - Featuring Berlin-Chemie, Bigfoot Biomedical, Digital Medics and Emperra Among Others

The global smart insulin pens market was valued at $94.8 million in 2020, and is estimated to reach $298.9 million by 2030, growing at a CAGR of 12.2% from 2021 to 2030.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Nov 09,2022

IDTechEx Examines the Medical Devices for Remote Patient Monitoring of Chronic Conditions

Diabetes is one of the health conditions most commonly covered by RPM programs worldwide, and with good reason. Today, RPM programs by leading players such as Onduo, Omada and Livongo (Teladoc) provide connected glucometers, unlimited supplies of glucose test strips, and through digital health, personalized insights and expert coaching.

#rpm

#coaching

#bgm

View Analyst & Ambassador Comments
Go to original news
Nov 09,2022

Senseonics to Present at the Stifel 2022 Healthcare Conference

Management is scheduled to participate on Tuesday, November 15, 2022 at 11:30am ET and will hold one-on-one meetings following.

CONFERENCES

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 09,2022

Eli Lilly to start rollout of Tempo personalized diabetes management platform

Eli Lilly and Co. recently announced it will soon roll out its Tempo personalized diabetes management platform in the U.S. The pharma giant described Tempo as its first connected platform. It includes three components: the Tempo Smart Button, a compatible TempSmart app, and the prefilled Tempo Pen insulin pen. The goal is personalized guidance for adults with diabetes. Lilly plans a phased rollout for the platform to select clinics starting later this year, followed by national availability targeted for 2023.

PRODUCT

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 10,2022

New IDTechEx Report Forecasts US$27Bn in 2033 for Electronic Skin Patches Market

IDTechEx have published their latest research, "Electronic Skin Patches 2023-2033", which estimates that the electronic skin patch market will grow to over US$27bn by 2033. In diabetes and heart monitoring, electronic skin patches have already transformed the industry. These devices may well enable a revolution for the rest of healthcare and beyond.

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 10,2022

Global Wearable Injectors Market to Reach $17.27 Billion by 2027 at a CAGR of 20.67%

The global wearable injectors market is projected to witness a CAGR of 20.67% during the forecast period to reach a total market size of US$17.271 billion by 2027, increasing from US$4.636 billion in 2020. Wearable injectors play an important role in managing non-communicable diseases like cardiovascular disease, cancer, diabetes, and autoimmune disease, amongst other diseases.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES